AAAAAA

   
Results: 1-4 |
Results: 4

Authors: Belldegrun, A Tso, CL Zisman, A Naitoh, J Said, J Pantuck, AJ Hinkel, A de Kernion, J Figlin, R
Citation: A. Belldegrun et al., Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial andbasic biology, HUM GENE TH, 12(8), 2001, pp. 883-892

Authors: Hinkel, A Tso, CL Gitlitz, BJ Neagos, N Schmid, I Paik, SH deKernion, J Figlin, R Belldegrun, A
Citation: A. Hinkel et al., Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma, J IMMUNOTH, 23(1), 2000, pp. 83-93

Authors: Mulders, P Tso, CL Gitlitz, B Kaboo, R Hinkel, A Frand, S Kiertscher, S Roth, MD deKernion, J Figlin, R Belldegrun, A
Citation: P. Mulders et al., Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines, CLIN CANC R, 5(2), 1999, pp. 445-454

Authors: van Ophoven, A Patel, B Belldegrun, A Hinkel, A Senge, T
Citation: A. Van Ophoven et al., Gene therapy and immunotherapy of advanced prostate cancer: from bench to bedside, AKT UROL, 30(2), 1999, pp. 78-88
Risultati: 1-4 |